Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06149559 · ClinicalTrials.gov registry record · Phase 2
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
A Phase 2 study of Generalized Myasthenia Gravis, sponsored by UCB Biopharma SRL.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 13
- Study locations
NCT06149559: Recruiting Phase 2 study of Generalized Myasthenia Gravis, sponsored by UCB Biopharma SRL.
NCT06149559 is a Phase 2 study of Generalized Myasthenia Gravis that is actively recruiting participants, run by UCB Biopharma SRL. The registered enrollment target is 12 participants, below the 131-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (91% lower). The trial reports 13 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06149559, a Phase 2 study of Generalized Myasthenia Gravis, is actively recruiting participants, sponsored by UCB Biopharma SRL.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \<18 years with generalized Myasthenia Gravis (gMG).
Conditions Studied
Interventions
- DRUG rozanolixizumab
Study Locations (13)
Other
- Mg0006 40290 - Bologna
- Mg0006 40144 - Milan
- Mg0006 40733 - Naples
- Mg0006 20340 - Fuchu-shi
- Mg0006 20339 - Ōbu
- Mg0006 20343 - Sagamihara
- Mg0006 40155 - Warsaw
- Mg0006 40734 - Warsaw
- Mg0006 20081 - Taipei
- Mg0006 20095 - Taipei
- Mg0006 40841 - Altindağ/ankara
- Mg0006 40836 - Kocaeli
Texas
- Mg0006 50574 - Denton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-06-14 |
| Est. Completion | 2026-08-17 |
| Phase | Phase 2 |
What NCT06149559 shows while recruiting
NCT06149559 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 131-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Generalized Myasthenia Gravis appearing as the primary indexed condition, and to 1 intervention - of which rozanolixizumab is the first listed.
NCT06149559 lists 13 locations in 2 states (Other, Texas).
Frequently Asked Questions
What is clinical trial NCT06149559 about?
NCT06149559 is a clinical study titled "A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis". The purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \<18 years with generalized Myasthenia Gravis (gMG).
What is the current status of trial NCT06149559?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2024-06-14. Estimated completion is 2026-08-17.
What conditions does trial NCT06149559 study?
This clinical trial studies the following conditions: Generalized Myasthenia Gravis.
What interventions are being tested in trial NCT06149559?
The interventions under investigation include: rozanolixizumab (DRUG).
Who is sponsoring clinical trial NCT06149559?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06149559 being conducted?
This trial has 13 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06149559's enrollment target sits among peer trials
12 22nd of 26 higher than 1 of 26 other Generalized Myasthenia Gravis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Generalized Myasthenia Gravis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
RECRUITING · Phase 2
-
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI